Sep. 9, 2009 (Business Wire) -- XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentations at the following upcoming conferences:
- Morgan Stanley Global Healthcare Unplugged Conference
Monday, September 14 at 2:45 p.m. Eastern Time
- 2009 Bank of America Merrill Lynch Smid Cap Conference
Tuesday, September 22 at 1:40 p.m. Eastern Time
To access the live presentations via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.
A replay of each Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the respective live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline (GSK). The FDA is currently reviewing GSK’s NDA for XP13512 as a potential treatment for moderate-to-severe primary restless legs syndrome in the United States. XenoPort’s product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity related to spinal cord injury, acute back spasms and Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark.
XNPT2G
